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Abstract: Stereotactic radiosurgery (SRS) maintains an important role in managing vestibular 
schwannoma (VS). Long-term clinical data have clearly established the safety and efficacy of the 
procedure for managing Koos low grade to intermediate grade VS. Historically, the procedure 
was developed via a multidisciplinary approach that involves physicians (eg, neurosurgeons 
and radiation oncologists) as well as clinical specialists (eg, radiation physicists). In this paper, 
we have reviewed current technical and clinical practices of SRS for VS from a procedural 
specialist’s perspective and from a clinician’s perspective.
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Introduction
The goal of this paper was to highlight the protocols and data that are relevant to the 




As first coined by Dr Lars Leksell, the term “stereotactic radiosurgery (SRS)” indi-
cates direct application of a precise spatial localization apparatus for a procedure 
that delivers a high dose of radiation accurately to a lesion inside the brain.1 The 
original localization apparatus envisioned by Dr Lars Leksell entailed a fixation 
metal frame (ie, stereotactic frame) in conjunction with the use of orthovoltage 
X-rays. Subsequently, technological advancements quickly replaced low-energy 
X-rays with megavoltage X-rays or high-energy gamma rays. Megavoltage X-rays 
are primarily produced from C-arm gantry-mount medical linear accelerators, and 
gamma rays are primarily produced from high-activity radioactive sources such as 
60Co, where its spectroscopy profile reveals two photon peaks at the energies of 1.17 
and 1.33 MeV, respectively.
Besides high-energy gamma rays or X-rays, mechanical alignment accuracy is 
another hallmark of the SRS procedure, whereby all of the radiation beams are aligned 
precisely toward a focal point in space, namely the isocenter. Current state-of-the-art 
SRS systems typically maintain mechanical beam alignment accuracy of 0.5 mm or 
less. Such a high standard of accuracy was historically set with the early Leksell Gamma 
Knife system that was pioneered by Dr Lars Leksell in the 1960s.2
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For example, the mechanical accuracy of the f irst 
Gamma Knife model U system installed in North America 
was reported to be less than 0.25 mm.3 This unit was deliv-
ered to the University of Pittsburgh in 1987 and the whole 
system weighed more than 20 tons with nearly 6,000 Ci 
of 60Co sources loaded and placed around a hemispherical 
surface to form a 2π solid angle. As a result, 201 individu-
ally shaped beams were individually aligned toward a single 
isocenter making the misalignment to <0.002 mm per beam, 
a remarkable engineering achievement for the system. Con-
sequently, the alignment accuracy of submillimeter isocenter 
has become the gold standard for benchmarking all SRS 
systems, especially applicable to the modern linac-based 
SRS systems.
Based on the number of isocenters typically used for 
treating VS, modern state-of-the-art SRS modalities can 
be classified into three types: 1) Leksell Gamma Knife 
system, including the recently released the Leksell Gamma 
Knife Icon system (Elekta AB, Stockholm, Sweden), where 
multiple isocenters (eg, N>3) are typically employed for 
treating a VS lesion; 2) Robotic X-band linear accelerator 
such as the latest CyberKnife M6 model (Accuray, Sunny-
vale, CA, USA), where non-isocenter beams on the order 
of a few hundreds are often used for treating VS; and 3) 
C-arm-based S-band linear accelerator such as the True-
Beam STx or Edge Model (Varian Oncology System, Palto 
Alto, CA, USA), where a single isocenter with multiple 
fixed or rotational arc beams are often employed for SRS 
treatment of VS. All these systems assert sub-millimeter 
beam alignment and mechanical accuracy on the order of 
0.5 mm or less.4
Such a high degree of beam alignment accuracy enables 
multiple cross-firing beams and/or multiple isocenters to be 
directed and superimposed inside an irregularly shaped target 
volume (such as the VS lesion). Cross-firing multiple beams 
from different angles toward a single or multiple isocenters 
are essential for SRS of VS in order to achieve a conformal 
dose distribution and adequate dose coverage of the target 
while sparing adjacent normal structures such as the cochlea 
and the brainstem.
Historically, stereotactic frame was used to establish the 
stereotactic coordinate system for the purpose of precisely 
aligning and focusing multiple beams for an SRS treatment. 
With the developments of linac flattening-filter-free (FFF) 
technology and in-room or on-board imaging guidance 
system such as stereoscopic kV imaging system of the 
CyberKnife system and on-board imaging system for the 
S-band linear accelerator, frameless SRS was introduced 
as an alternative solution to the traditional frame-based 
treatment.5,6 Notably, the latest GK Icon system also incor-
porated an on-board imaging system to provide frameless 
SRS solution in addition to the traditional frame-based SRS 
solution.7,8
One of the main issues of the frameless SRS is the 
intrafractional target shifts during the treatment that often 
require continuous monitoring and frequent corrections 
of the patient setups. This is in contrast to the frame-
based SRS where intrafractional target shifts are assumed 
minimal due to rigid frame fixations. The use of high-
dose-rate FFF beams for frameless SRS in part alleviated 
the problem by enabling the treatment to be delivered in 
minutes. However, concern for negative dose impact from 
potential interfractional target shifts particularly during a 
short treatment time remains. As a result, frameless SRS 
of VS has been largely employed and reported for fraction-
ated treatments while frame-based treatments are almost 
exclusively used for single-fraction SRS. Both frame-
based and frameless SRS of VS aim to leverage the highly 
conformal dose distributions created from the multi-beam 
cross-firing technique.
An example of VS case illustrating SRS beam cross-
firing principle is shown in Figure 1. In this example, 
multiple isocenters (N>5) are applied and the stereotactic 
coordinates (ie, x=116.8 mm, y=85.0 mm, z=115.4 mm) 
of the first isocentric beam delivery are indicated in the 
pop-up menu on the lower right corner. In addition, the 
cross-firing confocal beams aiming toward the first isocen-
ter are purposely shaped from several beam directions (cf, 
the pie diagram in the menu). In this case, all the beams 
surrounding the target are divided into eight independent 
sectors with each sector possessing variable beam sizes 
and directions. For example, sector 1 =16 mm of the beam 
diameter and it is directed from the patient’s anterior direc-
tion; sector 5 =16 mm of beam diameter and it is directed 
from the patient’s posterior direction; sector 2 to sector 4 
=16 mm of the beam diameter and it is directed from the 
patient’s left side; sector 6 and sector 8 =8 mm of the beam 
diameter and it is directed from the patient’s right side, and 
sector 7 =0 mm of the beam diameter or it is completely 
blocked. It should be noted that the combinations of these 
confocal beams of variable diameters create a conformal 
dose distribution surrounding the irregularly shaped VS 
target. It also facilitates the sparing of the brainstem that 
is adjacent to the target volume.
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Treatment planning
High-resolution MR imaging capability is critical for SRS of 
VS for the purpose of soft-tissue contrast. Volumetric thin-
slice MR imaging (such as 3D fast spoiled gradient-echo 
sequence with 1.0–1.5 mm in slice thickness) with gado-
linium contrast is typically employed for contouring the 
tumor volume. Volumetric T2 weighted MR imaging is 
often acquired for optic pathway structure definition and for 
identification of the cranial nerves as well as the cochlea. In 
order to resolve the bone interface within the target volume, 
volumetric CT imaging is also acquired to allow visualization 
of the target boundary as well as to enable crosscheck of the 
stereotactic coordinate definitions with the stereotactic coor-
dinates from the volumetric MR studies. With  sub-millimeter 
beam alignment accuracy, SRS beam targeting uncertain-
ties for the majority of VS treatments are considered to be 
minimal. As a rule of thumb, margins of less than 2 mm 
are generally employed when defining the planning target 
volume (PTV) based on the contrast enhancement volume 
of the gross target volume (GTV).
Furthermore, the historical data of SRS of VS were 
predominantly based on the clinical experiences of Gamma 
Knife radiosurgery (GKSRS), where the GTV to PTV mar-
gin was routinely set to 0 mm. As a result, the term “target 
volume” was widely cited without causing an ambiguity as to 
whether it refers to GTV or PTV. This caveat is particularly 
important when defining and evaluating treatment planning 
indices for SRS.
In general, three indices are commonly adopted by the 
user or the treatment planning software to optimize and to 
analyze an SRS treatment plan quality: 1) selectivity index 
(SI), 2) Paddick conformity index (PCI), and 3) gradient 








Figure 1 An illustration of multi-isocenter, multi-beam irradiation of a left-side vS lesion on a Gamma Knife icon system, where utilization of multiple isocenters and multiple 
directional shaped beams of variable beam diameters create the desired dose distribution.
Abbreviation: vS, vestibular schwannoma.


























where TV is the target volume, PIV(100%) is the isodose 
volume receiving 100% of the prescribed dose, PIV(50%) 
is the isodose volume receiving 50% of the prescribed dose, 
TIV is the target volume enclosed by the prescription isodose 
surface, that is, it equals to the union volume of the TV and 
PIV(100%).
It should be noted that all of the above indices are con-
structed based on the volume ratios of a selected isodose 
surface and the targets (either GTV or PTV). Physically, 
SI measures the target volume that coincides with the pre-
scribed isodose volume. By definition, SI increases as TIV 
increases for a given PIV(100%). It should be noted that SI 
=1.0 when the prescription isodose surface completely falls 
inside a target. In other words, SI is a parameter that detects 
over-coverage of the target volume by the prescribed dose. In 
comparison, PCI accounts for the target volume coverage by 
multiplying SI with the percentage of target volume cover-
age. Evidently SI = PCI if 100% target volume coverage is 
achieved. Ideally, PCI =1.0 for a perfect dose coverage and 
dose conformity. In reality, PCI ranges between 0.5 and 0.9 
for a VS treatment, and the higher the PCI value, the more 
conformal the SRS treatment plan. However, for cases where 
normal structure sparing plays an important role such as to 
avoid excess irradiation to the facial and cochlear nerves, PCI 
may be significantly lower due to intentional under coverage 
of the target volume (ie, significantly lower TIV/TV value 
in Equation 2).
Besides SI and PCI, GI measures the peripheral isodose 
falloff in the neighborhood of the target volume. From the 
expression of GI of Equation 3, by default, the lower the GI 
value, the sharper the dose fall off. A study examining the 
general dose falloff characteristics of various SRS lesion 
including VS treated with different SRS modalities has 
shown that a GI value of 2.83 would denote an average dose 
falloff following the classic inverse square law. If GI >2.83, 
it indicates shallower dose falloff versus the inverse square 
law and if GI <2.83, then it indicates a steeper dose falloff 
versus the inverse square law. For most single-fraction VS 
treatment cases, GI generally ranges between 2.6 and 3.1 
depending on the target shape and complexity, accounting 
for the sparing of near-by critical structures such as the 
cochlea and the brainstem. For special large VS treatment 
with planned under coverage of the target plus frequent use 
of large collimators with more scattering, a wider range of 
GI values may result and the user should be cautious. This 
is discussed in the following section.
An example case illustrating SRS of VS is shown in 
Figure 2.
In Figure 2, a dose of 12.5 Gy was prescribed to the 
contrast-enhanced GTV. It should be noted that the target vol-
ume for the case was divided into two separate components 
near inferior part of the lesion (noted on the image slice at 
z=127.6). This produced SI =0.64 for the case. With 100% 
target coverage, PCI =0.64*1.0=0.64. GI =2.99 suggests 
shallower dose falloff than the inverse square law.
Normal structure dose limits
Brainstem and cochlea are the major normal structures for 
SRS of VS. When SRS was first applied for treating VS, 
a peripheral dose as high as 18–20 Gy was used. Due to 
observed toxicities, the prescription dose was subsequently 
reduced to 12–14 Gy while still demonstrating equivalent 
local control. The latest ASTRO Quantec guideline also 
recommends an SRS dose of 12–14 Gy to preserve hearing. 
Given such a prescription dose to the target, the tolerance 
dose of the brainstem as specified by the AAPM 101 report 
(eg, the point maximum dose of 15 Gy and no more than 0.5 
cc receiving a dose of 10 Gy) is readily satisfied for majority 
of VS cases treated with single fraction SRS.
On the other hand, due to the proximity of cochlea (often 
for <1 mm from the target periphery), minimizing the dose to 
the cochlea is significantly more challenging than sparing the 
brainstem. Figure 3 illustrated such a case where the target 
and the cochlea were visualized on a T2 MR imaging study.
In the case of Figure 3, a tumor periphery dose of 12.5 
Gy was prescribed and significant beam shaping as illustrated 
in Figure 1 was applied. As a result, the cochlea received a 
mean dose of 4.5 Gy. As noted from Figure 3, the contoured 
structure of the cochlea is relatively small (eg, <0.1 mL). 
Various dose parameters besides the mean dose have been 
reported for the purpose of correlating a dose–response for 
SRS of VS.
Three most common dose surrogates for cochlea were 1) 
the point maximum dose, 2) central modiolus dose, and 3) 
volume-average mean dose. All of these have been reported as 
useful parameters to correlate with the hearing outcome post 
SRS.11–13 A study reported an inherent functional relationship 
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among these dose surrogates and found significant variability 
among these dose parameters.14 All dose parameters were 
found to correlate with the hearing change for a cohort of 
patients who underwent SRS of VS.
In particular, the point maximum dose has been found to 
be most useful in differentiating the risk probabilities. With 
95% confidence level (CL), a table of equivalent cochlear 
dose surrogates was established among the point maximum 
cochlear dose, modiolus cochlear dose, mean cochlear dose, 
and the dose to small hot spot volumes (such as 0.01–0.3 
cc) (Table 1).
As shown in Table 1, a point maximum cochlear dose 
of 12 Gy is therefore equivalent to a mean cochlear dose of 
5.6±0.1 Gy, a modiolus cochlear dose of 6.0±0.2 Gy, and so 
on. It is worth noting that the risk probabilities of sensory 
neuronal hearing loss (SNHL) at a given dose level such as 
the maximum dose of 12 Gy (ie, a mean dose of 5.6 Gy or 
a modiolus dose of 6.0) remain unknown. Current data are 
on the dose–response are limited and also conflictive when 
reporting the risk of SNHL at one dose level versus another. 
Nonetheless, a single fraction prescription dose of 12–14 Gy 
is a good general practice in minimizing the risk of SNHL. 
This corresponds to maintaining the point maximum cochlear 
dose to the level of 12–14 Gy or less.
Clinical perspective
VS is also known as the acoustic neuroma (AN) in the litera-
ture. Specifically, VS or AN arises from the Schwann cell of 
myelin sheath of the eighth cranial nerve. It is a benign lesion, 
typically with a slow growth rate of 1 mm or less per year. 
Most of VS occurred sporadically except for NF2 patients, 
where they tend to have significantly higher (3–4×) incidence 
rate and bilateral lesions also occur more commonly in NF2 
patients. The rate of incidence for sporadic VS also increases 
Figure 2 Axial dose distribution on a vS target volume superimposed onto the T1 post-contrast serial MR scans with a slice thickness of 1.5 mm.
Abbreviation: vS, vestibular schwannoma.
Figure 3 illustration of dose distribution for SRS of a left-side vS case with the goal of minimizing the dose to the cochlea whose location is indicated by the arrow.
Abbreviations: SRS, stereotactic radiosurgery; vS, vestibular schwannoma.





with the age and generally peaks for patients of 40–50 years 
of age. In general, lesion control for lesion in the setting of 
NF2 is inferior to those occurring sporadically.15
Tumor grade
Patients with VS are usually diagnosed with hearing loss 
and/or loss of speech discrimination from the pure tone and 
speech audiogram. The tumor is generally classified via 
the Koos grade, where Koos Grade 1 tumors are localized 
only within the internal auditory canal (IAC); Koos Grade 2 
tumors affect the IAC and the cerebellopintine angle; Koos 
Grade 3 tumors encroach the brainstem; Koos Grade 4 tumors 
cause distortions of the fourth ventricle.
Besides the tumor size, modern reports have also shown 
that cystic lesions generally respond better to SRS versus non-
cystic lesions. In general, macrocystic lesions tend to respond 
the best compared to the non-cystic or microcystic lesions.16
Treatment options and tumor control
SRS of VS is mostly applied to Koos Grade 1 and Grade 2 
tumors due to the delayed radiation response and concern for 
treatment-related toxicities with large target volumes. With a 
target peripheral dose of 12–14 Gy for a single fraction, the 
tumor local control is reported to exceed 90% for Grade 1 
and Grade 2 tumors regardless of the treatment modalities, 
including GKSRS and linac-based SRS.17 For large tumors 
such as Koos Grade 4, micro-surgery is recommended for 
fast relief of the mass effect and to prevent additional tumor 
growth that is found to be typically more significant for large 
tumors compared to small tumors. It should be noted that 
SRS can be a viable option for treating residual or recurrent 
VS post microsurgery with a high tumor control rate of 90% 
and low incidence of complications.18
For small VS tumors, observation was proposed as a reason-
able alternative for treatment management. However, several 
studies comparing SRS and observation have noted a detect-
able tumor growth rate of ~0.7 mm per year. Once the tumor 
growth has been established from the serial imaging studies of 
a patient, SRS is considered as a better option over observation 
for treatment management. Moreover, hearing preservation 
outcomes are superior to early treatment of smaller lesions.19
Koos high-grade tumors tend to have worse outcome 
compared to the lower grade tumors. One study has shown 
that the 5-year progression-free survival can decrease by as 
much as 5% when the tumor volume increases by ~3 cc.20 
How to improve local control for large VS lesions remains a 
challenge for SRS of VS tumors.
Patient follow-up and functional 
outcomes
After the SRS procedure, patients typically receive follow-
up MR scans every 6 months plus audiology and neurologic 
examinations. Based on the latest clinical data, hearing pres-
ervation post SRS reaches ~70% after 5 years.21,22 Studies 
have indicated that hearing preservation tends to correlate 
with early treatments within the first 2 years of diagnosis 
and the patient’s initial status such as the pure-tune average 
difference <10 dB between both ears.19,21,22
Risks of neurological deficits following SRS are low 
with an estimated risk of facial neuropathy and trigeminal 
neuropathy of ~1%–3%.23 However, all patients should be 
aware of the risk of malignant transformation of VS post 
SRS, which has been reported at 0.01%–0.1%.24,25 Similarly, 
the risk of secondary malignancy remains exceedingly low 
at 2.4% at 15 years.26
Pseudo-progression of VS is also found post an SRS 
procedure, which means that some tumors tend to enlarge in 
a transient period of the first 1–3 years during the follow-up.27 
For asymptomatic patients, observation is sufficient and for 
some patients close follow-ups may be needed to differentiate 
pseudo-progression from real significant progression within 
the first 3 years of completing the SRS procedures. Of note, 
in the case of true regrowth, repeat radiosurgery may be a 
safe and effective strategy.28
Controversies and developments
Single fractional SRS has established an excellent local tumor 
control rate in the range of 90%. It is minimally invasive and 
Table 1 equivalent cochlear dose parameters from an inherent functional formula












10.0 6.7±0.1 5.9±0.1 5.2±0.1 4.9±0.1 5.2±0.2
12.0 7.7±0.1 6.7±0.1 6.0±0.2 5.6±0.1 6.0±0.2
14.0 8.6±0.2 7.5±0.2 6.7±0.2 6.2±0.1 6.7±0.2
15.0 9.0±0.2 7.8±0.2 7.0±0.2 6.6±0.2 7.0±0.2
Notes: D(0.01 mL), D(0.02 mL), and D(0.03 mL) denote the doses to the isodose volumes of 0.01, 0.02, and 0.03 mL, respectively. The error bars in the table indicate 
mean±2SD.
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the procedure is convenient for patient as the same-day pro-
cedure. However, the technical complexity of the procedure 
is high, and not all patients have an easy access to a dedi-
cated SRS program. In contrast, conventionally fractionated 
radiotherapy of delivering 1.8–2 Gy fraction for 4–5 weeks 
has also shown to be effective for managing VS tumors.29
Hypofractionated SRS treatments with a removable ste-
reotactic frame have also been explored for the purpose of 
further improving the local control and hearing preservations. 
For hypofractionated SRS, a GTV to PTV margin such as 2 
mm is often included to account for intrafractional targeting 
uncertainties. It remains controversial as to the technique as 
well as to the dose fractionation schemes that would offer 
the best local dose control and/or the lower toxicity profiles 
versus the single fraction SRS.30
Although single fraction SRS has shown to be highly 
effective for small VS, managing large VS with SRS remains 
controversial.31 Some investigators have proposed hypofrac-
tionated treatments or multi-session volume-staged approach 
of managing these challenging cases with SRS. In the case 
of volume-staging, a single fraction SRS is first applied to 
a partial tumor volume distal to critical structures with the 
expectation of tumor shrinkage. Once tumor shrinkage is 
confirmed on interval imaging, an additional SRS procedure 
would be performed to treat the residual target volume. Others 
have proposed a hybrid approach of planned subtotal resec-
tion (STR) followed by radiosurgery with excellent rates of 
hearing and facial nerve preservation.32
Some investigators have argued that the key surgical 
objective for managing large VS has been shifted over the 
last decade from maximum tumor removal to nerve preserva-
tion. In a recent meta-analysis of planned STR followed by 
SRS, such an approach has been shown to produce excel-
lent functional outcomes with facial nerve preservation 
rate exceeded 95% and serviceable hearing preservation 
approaching 60% while achieving a tumor control rate of 
94%.33 This is a significant result considering relative high 
morbidity that associated with the attempt of achieving total 
surgical resection of the tumor.34,35
From a technical perspective, further enhancing the dose 
falloff or “sharpening the edge” between the target and the 
normal structure remains to be a challenge for the next gen-
eration of SRS device. With the rapid advancements of online 
stereotactic imaging localization such as that realized in the 
latest Gamma Knife Icon system plus significant elevation 
of radiation beam output such as that realized in the modern 
digitally controlled FFF linear accelerators, the use of SRS 
for VS is expected to expand with improved quality and 
efficiency of treatment planning. Ongoing technical develop-
ments continue to make the treatment device more integrated 
in terms of on-the-fly imaging and fast beam deliveries. This 
will continue to make SRS treatment become more accessible 
to all VS patients.
Summary
In this paper, we reviewed major technical and clinical per-
spectives of SRS of VS. The reader should be aware that no 
large randomized trials are available to guide a user on the 
best clinical and technical practices for SRS of VS given 
the pioneering effort of GKSRS. Nonetheless, a plethora 
of retrospective studies has been performed by the early 
adopters of the GKSRS and the data continued to expand 
with the advancement of SRS technology. Furthermore, 
expert consensus practice guidelines from recently published 
international society of stereotactic radiosurgery are useful 
for a user to review SRS of VS.
In summary, SRS has played an important role in manag-
ing VS. It is our expectation that such a role will continue to 
dominate and expand with continued advancements in the 
SRS technologies.
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